XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue and Contracts in Process (Tables)
3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Reconciliation of Revenue from Segments to Consolidated
Revenue from contracts with customers consists of the following (in millions):

Three Months Ended March 31,
 20242023
Infrastructure
$307.9 $311.7 
Life Sciences1.0 0.5 
Spectrum6.3 5.7 
Total revenue$315.2 $317.9 
Schedule of Accounts Receivable, net
Accounts receivables, net, from contracts with customers consist of the following (in millions):
March 31,
2024
December 31,
2023
 
Infrastructure
$262.6 $271.5 
Life Sciences0.5 0.3 
Spectrum1.6 1.4 
Total accounts receivables with customers$264.7 $273.2 
Accounts receivable, net, consisted of the following (in millions):
March 31,
2024
December 31, 2023
 
Contracts in progress$262.7 $271.7 
Unbilled retentions0.1 — 
Trade receivables2.0 1.9 
Other receivables4.6 5.2 
Allowance for expected credit losses (1)
(0.1)(0.4)
Total$269.3 $278.4 
(1) There was no change to the allowance for expected credit losses as a result of the adoption of ASU 2016-13 on January 1, 2023.
Schedule of Disaggregation of Revenue
The following table disaggregates DBMG's revenue by market (in millions):

Three Months Ended March 31,
 20242023
Transportation$100.4 $41.5 
Industrial84.1 91.3 
Commercial77.3 112.5 
Healthcare34.3 31.4 
Convention5.5 25.4 
Government2.7 3.7 
Energy2.2 2.7 
Leisure1.0 3.2 
Total revenue from contracts with customers$307.5 $311.7 
Other revenue0.4 — 
Total Infrastructure segment revenue$307.9 $311.7 
The following table disaggregates the Life Sciences segment's revenue by type (in millions):

Three Months Ended March 31,
20242023
Systems and consumables revenue$1.0 $0.5 
Total Life Sciences segment revenue$1.0 $0.5 
The following table disaggregates the Spectrum segment's revenue by type (in millions):

Three Months Ended March 31,
20242023
Broadcast station$6.3 $5.2 
Other— 0.5 
Total Spectrum segment revenue$6.3 $5.7 
Schedule of Costs and Recognized Earnings in Excess of Billings and Billings in Excess of Costs and Recognized Earnings on Uncompleted Contracts
Contract assets and contract liabilities and recognized earnings consisted of the following (in millions):
March 31,
2024
December 31, 2023
Costs incurred on contracts in progress$2,979.0 $2,811.8 
Estimated earnings548.2 510.1
Contract revenue earned on uncompleted contracts3,527.2 3,321.9 
Less: progress billings3,570.4 3,356.8 
$(43.2)$(34.9)
The above is included in the accompanying Condensed Consolidated Balance Sheets under the following line items:
Contract assets$82.2 $118.6 
Contract liabilities(125.4)(153.5)
$(43.2)$(34.9)
Schedule of Contract with Customer, Asset and Liability
March 31,
2024
December 31,
2023
 
Cost in excess of billings and estimated earnings
$46.4 $73.8 
Conditional retainage35.8 44.8 
Contract assets$82.2 $118.6 
Billings in excess of costs and estimated earnings
$(194.5)$(229.3)
Conditional retainage69.1 75.8 
Contract liabilities$(125.4)$(153.5)
Schedule of Remaining Performance Obligations
As of March 31, 2024, the transaction price allocated to remaining unsatisfied performance obligations consisted of the following (in millions):
 Within One YearWithin Five YearsTotal
Healthcare$175.0 $194.5 $369.5 
Commercial219.0 0.4 219.4 
Industrial174.3 0.4 174.7 
Transportation107.0 32.1 139.1 
Government9.8 — 9.8 
Convention8.2 — 8.2 
Energy
1.9 — 1.9 
Leisure2.6 — 2.6 
Remaining unsatisfied performance obligations$697.8 $227.4 $925.2